Comparative Evaluation of AI-Based and Non-AI Genomic Biomarkers for Predicting Lung Cancer Treatment Response: A Systematic Review
Conventional genomic biomarkers remain central to current lung cancer treatment decisions because of their established clinical validity, and AI-based genomic models show promise for improving prediction and patient stratification, but their clinical utility remains uncertain without stronger prospective validation.